Kallyope Enters Phase 2 With First-in-class Oral Approach for the Treatment of Both Obesity and Type 2 Diabetes Portfolio News / Karina Tin September 27, 2023 Kallyope Enters Phase 2 With First-in-class Oral Approach for the Treatment of Both Obesity and Type 2 Diabetes Read More »
Escient Pharmaceuticals Initiates Clinical Proof-of-Concept Study of EP262, A First-In-Class Oral MRGPRX2 Antagonist, In Chronic Inducible Urticaria Portfolio News / Karina Tin September 25, 2023 Escient Pharmaceuticals Initiates Clinical Proof-of-Concept Study of EP262, A First-In-Class Oral MRGPRX2 Antagonist, In Chronic Inducible Urticaria Read More »
Accent Therapeutics Bolsters Leadership Team with Key Executive Hires Portfolio News / Karina Tin September 21, 2023 Accent Therapeutics Bolsters Leadership Team with Key Executive Hires Read More »
Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-9805, an Oral, Covalent, Mutant-Selective KRASG12D(ON) Inhibitor Portfolio News / Karina Tin September 19, 2023 Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-9805, an Oral, Covalent, Mutant-Selective KRASG12D(ON) Inhibitor Read More »
Eikon Therapeutics Announces Business Update Highlighting Pipeline and Clinical Development Progress Portfolio News / Karina Tin September 11, 2023 Eikon Therapeutics Announces Business Update Highlighting Pipeline and Clinical Development Progress Read More »
Nurix Announces Strategic Collaboration with Seagen Combining Industry Leading Technologies of Targeted Protein Degradation and Antibody-Drug Conjugation to Advance an Innovative New Class of Cancer Therapeutics Portfolio News / Karina Tin September 7, 2023 Nurix Announces Strategic Collaboration with Seagen Combining Industry Leading Technologies of Targeted Protein Degradation and Antibody-Drug Conjugation to Advance an Innovative New Class of Cancer Therapeutics Read More »
